TrialThe lancet. Gastroenterology & hepatology2024

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Do-Youn Oh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.